公开(公告)号：US10851116B2

公开(公告)日：2020-12-01

申请号：US16479375

申请日：2018-01-19

Applicant: LEO Pharma A/S

Inventor： Daniel Rodriguez Greve ,  Tue Heesgaard Jepsen ,  Mogens Larsen ,  Andreas Ritzen

IPC: C07D519/00 ,  A61K31/519

Abstract: The present invention relates to a compound according to formula I wherein R1 is alkyl; n is 1 or 2; R2 is selected from the group consisting of hydrogen, cyano, —SO2Ra, —SO2NRbRc, —C(O)Rb, phenyl and 5- and 6-membered heteroaryl or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to pharmaceutical compositions comprising said compounds, and to methods of treating proliferative or inflammatory skin disorders with said compounds.

公开(公告)号：US10703751B2

公开(公告)日：2020-07-07

申请号：US16477249

申请日：2018-01-10

Applicant: LEO Pharma A/S

Inventor： Jens Larsen ,  Mogens Larsen ,  Lars Kyhn Rasmussen ,  Andreas Ritzen ,  Tine Marianne Duus

IPC: C07D471/04 ,  A61K45/06

Abstract: The present invention relates to a compound according to formula (I) or pharmaceutically acceptable salts, hydrates, or solvates thereof; wherein R1 is C1-alkyl, R2 is C1-alkyl, R3 is C2-alkyl, R4 is hydrogen, R5 is hydrogen. The invention relates further to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to said compounds for use in the treatment autoimmune diseases and to intermediates for the preparation of said compounds.

公开(公告)号：US10799507B2

公开(公告)日：2020-10-13

申请号：US16483079

申请日：2018-02-01

Applicant: LEO Pharma A/S

Inventor： Mogens Larsen ,  Andreas Ritzen ,  Bjarne Nørremark ,  Daniel Rodriguez Greve

IPC: C07D487/04 ,  A61K31/519

Abstract: The present invention relates to a compound according to formula (I) wherein X represents NH or O; n is an integer selected from 1-3; Y represents a bond, —C(O)O—*, —C(O)OR3—* or —C(O)NHR3—*; W is selected from the group consisting of phenyl, pyridyl, (C3-C7)cycloalkyl and 4-6 membered heterocycloalkyl; or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.